HUTCHMED (China) Limited (H7T1) - Cash Flow Conversion Efficiency
Based on the latest financial reports, HUTCHMED (China) Limited (H7T1) has a cash flow conversion efficiency ratio of -0.140x as of December 2022. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (€-89.37 Million ≈ $-104.48 Million USD) by net assets (€636.87 Million ≈ $744.57 Million USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
HUTCHMED (China) Limited - Cash Flow Conversion Efficiency Trend (2016–2024)
This chart illustrates how HUTCHMED (China) Limited's cash flow conversion efficiency has evolved over time, based on yearly financial data. Read HUTCHMED (China) Limited (H7T1) financial obligations for a breakdown of total debt and financial obligations.
HUTCHMED (China) Limited Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of HUTCHMED (China) Limited ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Beijing Zhong Ke San Huan High-Tech Co Ltd
SHE:000970
|
0.007x |
|
Ströer SE & Co. KGaA
F:SAX
|
0.231x |
|
Longshine Technology Co Ltd
SHE:300682
|
0.020x |
|
Huada Automotive Tech Corp Ltd
SHG:603358
|
-0.009x |
|
Sichuan Anning Iron and Titanium Co
SHE:002978
|
-0.072x |
|
Roshow Technology Co Ltd
SHE:002617
|
-0.024x |
|
Triumph Science & Technology Co Ltd
SHG:600552
|
-0.016x |
|
Mtar Technologies Limited
NSE:MTARTECH
|
0.016x |
Annual Cash Flow Conversion Efficiency for HUTCHMED (China) Limited (2016–2024)
The table below shows the annual cash flow conversion efficiency of HUTCHMED (China) Limited from 2016 to 2024. For the full company profile with market capitalisation and key ratios, see how much is HUTCHMED (China) Limited worth.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | €771.85 Million ≈ $902.38 Million |
€497.00K ≈ $581.05K |
0.001x | -99.78% |
| 2023-12-31 | €743.39 Million ≈ $869.10 Million |
€219.26 Million ≈ $256.34 Million |
0.295x | +169.93% |
| 2022-12-31 | €636.87 Million ≈ $744.57 Million |
€-268.60 Million ≈ $-314.02 Million |
-0.422x | -114.67% |
| 2021-12-31 | €1.04 Billion ≈ $1.22 Billion |
€-204.22 Million ≈ $-238.76 Million |
-0.196x | -64.27% |
| 2020-12-31 | €518.95 Million ≈ $606.71 Million |
€-62.07 Million ≈ $-72.56 Million |
-0.120x | +53.75% |
| 2019-12-31 | €312.90 Million ≈ $365.82 Million |
€-80.91 Million ≈ $-94.59 Million |
-0.259x | -224.54% |
| 2018-12-31 | €412.25 Million ≈ $481.97 Million |
€-32.85 Million ≈ $-38.40 Million |
-0.080x | -332.07% |
| 2017-12-31 | €484.97 Million ≈ $566.98 Million |
€-8.94 Million ≈ $-10.46 Million |
-0.018x | +60.68% |
| 2016-12-31 | €204.06 Million ≈ $238.57 Million |
€-9.57 Million ≈ $-11.19 Million |
-0.047x | -- |
About HUTCHMED (China) Limited
HUTCHMED (China) Limited, together with its subsidiaries, discovers, develops, and commercializes targeted therapeutics and immunotherapies to treat cancer and immunological diseases in Hong Kong, the United States, and internationally. The company offers Fruquintinib, a selective and potent oral inhibitor of vascular endothelial growth factor receptors for treatment of colorectal cancer (CRC), b… Read more